About Focus Pipeline Investors Contact About Timber Pharmaceuticals About Us Management Team Board of Directors Partnerships Meet the Team Timber is committed to developing treatments for unmet needs in medical dermatology. To deliver on our promise to you, our team is made of world class advisors and a strong leadership team with a proven track record of success. John Koconis, MBA CHAIRMAN & CHIEF EXECUTIVE OFFICER John has had a highly accomplished career as both a strategic and operational leader in the pharmaceutical sector with over 25 years of experience leading successful teams in global markets and launching multiple market-leading products. John brings a unique perspective through his experience in broad, specialty and rare/orphan dermatology development and commercialization. Read more Zachary Rome CHIEF OPERATING OFFICER Zach is a biopharmaceutical inventor, entrepreneur and executive. He is a Co-Founder of Timber and has served as the Company’s President since its inception. Zach is also a Partner at TardiMed Sciences, a life sciences company creation firm. At TardiMed, Zach has helped to form several life sciences companies that span multiple therapeutic areas and stages of development. Read more About Focus Pipeline Investors Contact Legal Notice | © 2020 by Timber Pharmaceuticals LLC

About Focus Pipeline Investors Contact Our Focus Overview Congenital Ichthyosis Tuberous Sclerosis Complex Localized Scleroderma Congenital Icthyosis Congenital Ichthyosis (CI) is a group of rare genetic keratinization disorders that leads to dry, thickened, and scaling skin. About Focus Pipeline Investors Contact Legal Notice | © 2020 by Timber Pharmaceuticals LLC

About Focus Pipeline Investors Contact Our Development Pipeline Overview TMB-001 TMB-002 TMB-003 Timber is strategically building a development pipeline in rare dermatologic diseases that have no approved treatments. Our three core development programs have all received Orphan Drug status. In addition, all of our investigational products have significant market expansion potential into major medical dermatology indications such as acne, port wine stains and tissue scarring. Clinical proof of concept has already been established in two of our mid-stage clinical development programs. About Focus Pipeline Investors Contact Legal Notice | © 2020 by Timber Pharmaceuticals LLC

About Focus Pipeline Investors Contact Investor Relations Events & Presentations Timber Pharma TMB-001 Ph 2b Study Results Conference Call - November 22, 2021 View Webcast H.C. Wainwright 23rd Annual Global Investment Conference - September 13th - 15th, 2021 View Webcast Investor Overview SEC Filings Press Releases Corporate Governance Events & Presentations Contact Investor Relations Stock Quote Investor Presentation September 2021 Click to Download About Focus Pipeline Investors Contact Legal Notice | © 2020 by Timber Pharmaceuticals LLC